Αρχική World News Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had... World News Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy Από Ogkologos - 16 Ιουνίου, 2025 711 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ΗΛΕΚΤΡΟΧΗΜΕΙΟΘΕΡΑΠΕΙΑ: Η ΝΕΑ ΠΡΩΤΟΠΟΡΙΑΚΗ ΠΡΟΣΕΓΓΙΣΗ ΓΙΑ ΘΕΡΑΠΕΙΑ ΟΓΚΩΝ 10 Σεπτεμβρίου, 2019 Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of... 17 Απριλίου, 2023 What Do You Put In Your Pocket? 28 Απριλίου, 2021 Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer 21 Μαΐου, 2024 Φόρτωση περισσοτέρων HOT NEWS Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer Virtual Reality Found to Benefit Cancer Patients’ Mental Health People who’ve had radiotherapy shape our new policy calls Scientists Find Genetic Changes Linked to Cancer in Children